Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Melanoma and Skin Cancer

Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis

Melanoma Res

Kreuz M, de Moraes FCA, Sano VKT, Westphal Filho FL, Silva ALS, Kelly FA

doi: 10.1097/CMR.0000000000001006

Melanoma and Skin Cancer

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma

Br J Dermatol

McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, de Lima Vazquez V, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Abrão Possik P, Robles Espinoza CD, Ito F, In GK

doi: 10.1093/bjd/ljae401

Psoriatic Arthritis

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

J Rheumatol

Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W

doi: 10.3899/jrheum.2024-0923

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Psoriasis

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

Acta Derm Venereol

Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J, Han C, Kirby B

doi: 10.2340/actadv.v104.41053

Melanoma and Skin CancerFurther Publications Rheumatology

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

J Autoimmun

Tenstad HB, Ruhlmann CH, Möller S, Kjaer S, Bastholt L, Just SA, Lindegaard H

doi: 10.1016/j.jaut.2025.103400

Immunotherapy

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Ann Oncol

Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Obermannová RL, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Sanchez CB, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E

doi: 10.1016/j.annonc.2024.10.829

Melanoma and Skin Cancer

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Melanoma Res

Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C

doi: 10.1097/CMR.0000000000000973

Related content

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort